Released Nov 4, 2021, after the close
10-Q filed Nov 4, 2021, 35 days after period end · 0001564590-21-054499
Q3 2021 · 10-Q
Revenue$6.25M$6.25M −81.9% vs Q3 2020no prior Q2 2021 on file
Net Income-$18.80M-$18.80M N/M vs Q3 2020N/M vs Q2 2021
EPS Diluted-$0.41-$0.41 N/M vs Q3 2020N/M vs Q2 2021
Operating Income-$18,875,000N/M
Operating Cash Flowderived-$18,882,000N/M
Free Cash Flowderived-$18,882,000N/M
Margins · derived
Operating margin-301.8%−290.2 pt vs Q3 2020
Net margin-300.7%−291.0 pt vs Q3 2020
What the release said
The release
Same quarter
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Revenue | $6.25M | $34.61M | $4.23M | $4.29M |
| Net Income | -$18.80M | -$3.35M | -$25.00M | -$21.54M |
| EPS Diluted | -$0.41 | -$0.09 | -$0.96 | -$0.87 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR